Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.

Background: Targeting biopsy (TBx) of suspicious lesions combined with random systematic biopsy (SBx) improves detection rates of prostate cancer (PCa) during magnetic resonance imaging (MRI)/ultrasound (US) fusion prostate biopsy. However, this combination increases the number of biopsy cores, prolongs the procedure time, and increases complications and costs, leading to the overdiagnosis of clinically insignificant PCa (ciPCa). This study aims to evaluate the optimal sampling design to achieve a detection rate of clinically significant PCa (csPCa) equal to standard TBx with SBx with fewer biopsy cores.

The use of prostate specific antigen density to predict clinically significant prostate cancer.

The purpose of this study was to assess the predictive value of prostate specific antigen density (PSAD) for detection of clinically significant prostate cancer in men undergoing systematic transrectal ultrasound (TRUS)-guided prostate biopsy. We retrospectively analyzed data of men who underwent TRUS-guided prostate biopsy because of elevated PSA (≤ 20 ng/ml) or abnormal digital rectal examination. Receiver operating characteristic curve analysis to compare PSA and PSAD performance and chi-square automatic interaction detector methodologies were used to identify predictors of clinically significant cancer (Gleason score ≥ 7 or international society of urological pathology grade group ≥ 2).

Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.

Objectives: To evaluate comparatively fluorescence in situ hybridization (FISH) and cytology performed on exfoliated urothelial cells obtained from voided urine and bladder washings as a method of diagnosis and follow-up in patients with transitional cell carcinoma (TCC) of the bladder.

Methods: Thirty patients with confirmed bladder TCC, 10 patients enrolled in cystoscopy follow-up for previous bladder tumors, and 10 patients with bladders free of tumor without a previous history of bladder TCC underwent cytologic examination and FISH performed on voided urine and bladder washing specimens. The FISH probes were targeted to chromosomes 7 and 9.

Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells.

Background: During peritoneal dialysis, mesothelial cells become detached from the peritoneum and accumulate in the dialysate. Our aim was to evaluate the potential of peritoneal effluent (PF)-derived human peritoneal mesothelial cells (HPMC) as target for gene therapy. We used erythropoietin (EPO) as our target gene.